The cell and gene therapy (CGT) industry is at an inflection point. As FDA approvals for CGT products accelerate year after year, manufacturers face a critical challenge: how do you scale production of living therapies — each one biologically unique — without sacrificing quality or breaking the bank?
The answer, increasingly, is artificial intelligence.
Our latest BCC Pulse Report explores how AI, robotics, and machine learning are being deployed across the entire CGT value chain. The findings are striking. Companies like OmniaBio are leveraging AI-enabled manufacturing to target cost reductions of nearly 50%, while Dyno Therapeutics is using AI to design next-generation viral delivery vectors that are more efficient and less likely to trigger immune responses.
Investment Is Surging
AI funding in the biopharma sector increased by nearly $2 billion compared to 2021, with approximately 71% of investments directed toward biopharma AI applications. Roche has committed up to $1 billion to partner with Dyno Therapeutics, and Arsenal Bio raised $325 million in Series C funding for AI-enabled T-cell therapies.
But this isn't just about the money. The real story is about overcoming the fundamental limitations of conventional manufacturing — systems designed for standardized, linear operations that simply can't handle the dynamic, variable nature of living biological therapies. AI-specific platforms are changing that equation entirely.
Download the Report Overview
Want the full picture? Download the free overview of our report AI Impact on Global Cell and Gene Therapy Tools and Reagents Market to explore key use cases, adoption trends by region, and the investment landscape shaping the future of CGT manufacturing.
→ Download the Free Report Overview
